Literature DB >> 7579495

Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer.

R Murray1, P Pitt.   

Abstract

One hundred and twelve post menopausal or post oophorectomy women with advanced breast cancer (BC) who had all previously had aminoglutethimide (AG) were treated with the potent aromatase inhibitor 4-hydroxy androstenedione (4-OHA). Twenty three women (21%) had a partial response to 4-OHA while another twenty five patients (22%) had stabilization of previously progressing disease. Patients responded to 4-OHA both after previously responding to then relapsing on, and after failing to respond to aminoglutethimide. Toxicity was minimal. This study shows that potent aromatase inhibition with 4-OHA is effective in women with advanced BC who have already been treated with a less potent aromatase inhibitor, and suggests that relative changes in oestrogen levels may be more important than absolute levels.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7579495     DOI: 10.1007/BF00665976

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  9 in total

1.  Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment.

Authors:  P E Lønning; M Dowsett; A Jones; D Ekse; S Jacobs; F McNeil; D C Johannessen; T J Powles
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

2.  4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer.

Authors:  R C Coombes; S W Hughes; M Dowsett
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

Review 3.  Aromatase inhibitors: basic and clinical studies.

Authors:  A M Brodie; R C Coombes; M Dowsett
Journal:  J Steroid Biochem       Date:  1987       Impact factor: 4.292

4.  Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study.

Authors:  K Höffken; W Jonat; K Possinger; M Kölbel; T Kunz; H Wagner; R Becher; R Callies; P Friederich; W Willmanns
Journal:  J Clin Oncol       Date:  1990-05       Impact factor: 44.544

5.  Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma.

Authors:  R J Santen; T J Worgul; A Lipton; H Harvey; A Boucher; E Samojlik; S A Wells
Journal:  Ann Intern Med       Date:  1982-01       Impact factor: 25.391

6.  4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer.

Authors:  R C Coombes; P E Goss; M Dowsett; G Hutchinson; D Cunningham; M Jarman; A M Brodie
Journal:  Steroids       Date:  1987 Jul-Sep       Impact factor: 2.668

7.  A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer.

Authors:  R J Santen; T J Worgul; E Samojlik; A Interrante; A E Boucher; A Lipton; H A Harvey; D S White; E Smart; C Cox; S A Wells
Journal:  N Engl J Med       Date:  1981-09-03       Impact factor: 91.245

8.  Medical adrenalectomy in patients with advanced breast cancer resistant to anti-oestrogen treatment.

Authors:  R M Murray; P Pitt
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

9.  A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.

Authors:  M Dowsett; A L Harris; R Stuart-Harris; M Hill; B M Cantwell; I E Smith; S L Jeffcoate
Journal:  Br J Cancer       Date:  1985-10       Impact factor: 7.640

  9 in total
  9 in total

Review 1.  Clinical pharmacokinetics of aromatase inhibitors and inactivators.

Authors:  Per Lønning
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Aromatase inhibitors and inactivators for breast cancer therapy.

Authors:  Per E Lønning
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 3.  Aromatase inhibitors in the treatment of postmenopausal breast cancer.

Authors:  E Bajetta; N Zilembo; E Bichisao
Journal:  Drugs Aging       Date:  1999-10       Impact factor: 3.923

Review 4.  Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.

Authors:  L R Wiseman; K L Goa
Journal:  Drugs Aging       Date:  1996-10       Impact factor: 3.923

Review 5.  Is there a growing role for endocrine therapy in the treatment of breast cancer?

Authors:  P E Lønning
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 6.  Comprehensive pharmacology and clinical efficacy of aromatase inhibitors.

Authors:  V C Njar; A M Brodie
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

Review 7.  Risks and benefits of aromatase inhibitors in postmenopausal breast cancer.

Authors:  L B Michaud; A U Buzdar
Journal:  Drug Saf       Date:  1999-10       Impact factor: 5.606

Review 8.  Estrogen receptor alpha in human breast cancer: occurrence and significance.

Authors:  S Ali; R C Coombes
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-07       Impact factor: 2.673

Review 9.  Understanding the mechanisms of aromatase inhibitor resistance.

Authors:  William R Miller; Alexey A Larionov
Journal:  Breast Cancer Res       Date:  2012-01-19       Impact factor: 6.466

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.